Fungal pathogenesis depends on virulence factors: thermal dimorphism (switching morphology to evade immunity), production of melanin-like compounds that resist phagocytosis, and secretion of proteases and lipases. Opportunistic fungi (Candida, Cryptococcus) exploit immunocompromise; endemic fungi (Histoplasma, Coccidioides) cause primary infections in immunocompetent hosts. Chitin-β-glucan cell walls trigger distinct innate immune recognition patterns compared to bacteria.
You already understand host-pathogen interactions and the structure of the fungal cell wall. Fungal pathogenesis builds on both: the same chitin and β-glucan architecture that defines fungi as a kingdom also determines how the immune system detects them, and the virulence strategies fungi deploy are fundamentally different from those of bacteria or viruses. Understanding these differences is essential because fungal infections are increasing in clinical importance and are notoriously difficult to treat.
The most clinically significant fungal virulence mechanism is thermal dimorphism. Several important pathogens — *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Coccidioides immitis*, and *Talaromyces marneffei* — exist as molds in the environment (at 25°C) but convert to yeast forms at body temperature (37°C). This shape-shift is not cosmetic: the yeast form is the pathogenic form, and the transition involves wholesale changes in cell wall composition, surface antigen expression, and metabolic activity that help the organism evade phagocytosis and survive inside macrophages. *Histoplasma*, for example, is inhaled as mold conidia (spores), which convert to small yeast cells in the warm lung. These yeasts are phagocytosed by alveolar macrophages but survive and replicate *inside* the phagosome by neutralizing its acidic pH — a strategy strikingly parallel to *Mycobacterium tuberculosis*, though the molecular mechanisms differ entirely.
The division between opportunistic and endemic fungi is the second organizing framework. Opportunistic fungi like *Candida albicans*, *Cryptococcus neoformans*, and *Aspergillus fumigatus* rarely cause serious disease in immunocompetent hosts — they exploit deficits in immune function, particularly low CD4+ T cell counts (HIV/AIDS), neutropenia (chemotherapy), or broad-spectrum antibiotic use (which disrupts competing bacterial flora and allows *Candida* to overgrow). *Cryptococcus* evades phagocytosis with a thick polysaccharide capsule and produces melanin that scavenges free radicals, protecting it from oxidative killing. Endemic fungi, by contrast, have evolved virulence mechanisms potent enough to cause disease in healthy individuals — but only in specific geographic regions where the mold form grows in soil. *Coccidioides* is endemic to the American Southwest; *Histoplasma* to the Ohio and Mississippi River valleys. Knowing where a patient has lived or traveled is often the single most important diagnostic clue for these infections.
The immune response to fungi relies heavily on innate recognition of cell wall components. Pattern recognition receptors — particularly Dectin-1 (which binds β-glucan) and TLR2 (which detects phospholipomannan and other fungal surface molecules) — trigger inflammatory cytokine production and phagocyte activation. Effective clearance of most fungal infections requires Th1 and Th17 CD4+ T cell responses that activate macrophages and recruit neutrophils, which is precisely why HIV-mediated CD4 depletion predisposes so strongly to fungal disease. The fungal cell wall is also the reason antifungal therapy is challenging: because fungal cells are eukaryotic, most targets that would kill the fungus would also harm the host. The major antifungal drug classes target the few structures unique to fungi — ergosterol in the fungal membrane (targeted by azoles and amphotericin B) and β-glucan synthesis in the cell wall (targeted by echinocandins). This limited target space explains why antifungal resistance is an escalating clinical problem.
No topics depend on this one yet.